Breaking News Instant updates and real-time market news.

CATB

Catabasis Pharmaceuticals

$1.83

0.07 (3.98%)

, SRPT

Sarepta

$46.60

2.26 (5.10%)

08:31
09/28/17
09/28
08:31
09/28/17
08:31

Catabasis to present results from Sarepta collaboration at ICWMS

Catabasis Pharmaceuticals (CATB) said it will present data from the Catabasis and Sarepta (SRPT) joint research collaboration in Duchenne muscular dystrophy at the 22nd International Congress of the World Muscle Society in a poster presentation titled "Edasalonexent, an NF-kB inhibitor, enhances myotube formation in vitro, and increases exon-skipped sarcolemmal dystrophin in muscle of mdx mice" during poster session 4 on Thursday, October 5, 2017 from 17:00 - 18:30 CEST. The International Congress of the World Muscle Society is being held October 3 - 7, 2017, at the Palais du Grand Large in Saint Malo, France.

CATB

Catabasis Pharmaceuticals

$1.83

0.07 (3.98%)

SRPT

Sarepta

$46.60

2.26 (5.10%)

CATB Catabasis Pharmaceuticals
$1.83

0.07 (3.98%)

03/17/17
OPCO
03/17/17
NO CHANGE
Target $11
OPCO
Outperform
Oppenheimer remains bullish on Catabasis Pharmaceuticals
Oppenheimer analyst Hartaj Singh remains bullish on Catabasis Pharmaceuticals after quarterly results. The analyst notes that the company is hvaing an eventful 2017 with edasalonexent not meeting its primary and secondary endpoints in Part B of the MoveDMD clinical trial. However, a potential efficacy signal was noted and the focus on the earnings call was Part C of the MoveDMD trial, he argues, adding that he is "cautiously optimistic" that long-term treatment in Part C may show enough of an efficacy signal for the drug to move forward into further clinical trials. Singh reiterates an Outperform rating and $11 price target on the shares.
06/21/17
WEDB
06/21/17
NO CHANGE
WEDB
Sentiment towards Catabasis Pharmaceuticals improving, says Wedbush
Wedbush analyst Liana Moussatos says recent comments by investors indicate that sentiment towards Catabasis Pharmaceuticals is improving. The analyst notes that the stock dropped sharply after the company's drug missed its primary endpoint in a study in January. However, she says that investors are starting to put more emphasis on "the totality of the company's data," and beginning to look forward to 24 week Part C results in Q3. The analyst adds that the company's drug edasalonexent when combined with exon-skipping treatment has shown signs of boosting dystrophin production, while its CAT-5571 appears to have "positively affected a cystic fibrosis disease process in an experimental cell model." She keeps a $4 price target and an Outperform rating on the stock.
08/14/17
HCWC
08/14/17
NO CHANGE
Target $9
HCWC
Buy
Catabasis Pharmaceuticals price target raised to $9 from $8 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Catabasis Pharmaceuticals to $9 and keeps a Buy rating on the shares. The MoveDMD trial Part C data, expected in Q3, is required to move edasalonexent into pivotal trials, the analyst tells investors in a research note. She expects to see a numerical improvement in multiple functional assessments, which "may be sufficient" to guide the design of the pivotal trial and move the program forward.
08/14/17
OPCO
08/14/17
NO CHANGE
Target $4
OPCO
Outperform
Catabasis Pharmaceuticals price target lowered to $4 from $9 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Catabasis Pharmaceuticals to $4 from $9 as a comprehensive Phase 3 program potentially pushes out sales timelines and reduces sales potential. The analyst reiterates an Outperform rating on the shares.
SRPT Sarepta
$46.60

2.26 (5.10%)

09/07/17
OPCO
09/07/17
NO CHANGE
Target $76
OPCO
Outperform
Data removes another overhang on Sarepta, says Oppenheimer
Oppenheimer analyst Hartaj Singh notes that Sarepta provided an update on its 4053-101 study, a two-part study designed to assess the safety, tolerability and pharmacokinetics of four dose levels of SRP-4053 and an open-label evaluation of SRP-4053 in patients with deletions amenable to exon 53 skipping. The positive result removes an overhang on Sarepta, he contends, as some investors had posited that weak biopsy results from 4053-101 could reignite the Exondys 51 approval controversy from 2H16. The analyst reiterates an Outperform rating and $76 price target on the shares.
09/15/17
RBCM
09/15/17
INITIATION
RBCM
Outperform
Sarepta initiated on positive catalysts at RBC Capital
As noted earlier, RBC Capital started coverage of Sarepta with a $64 price target and an Outperform rating. Analyst Matt Eckler identified the company as one of his top small/mid-cap biotech picks. The analyst says that the commercial opportunity of the company's Exondys 51 is greater than the market believes, while the company's pipeline is "underappreciated" and it has other potential catalysts.
09/25/17
JPMS
09/25/17
NO CHANGE
JPMS
Neutral
JPMorgan 'somewhat cautious' on PTC into FDA panel meeting
JPMorgan analyst Anupam Rama says he remains "somewhat cautious" on shares of PTC Therapeutics (PTCT) with the FDA's Peripheral and Central Nervous Systems Drugs Advisory Committee convening on September 28 to review the company's Translarna for the treatment of non-sense mutation Duchenne muscular dystrophy. Translarna has an FDA action date of October 24. The analyst cites the drug's "mixed" Phase 2 and Phase 3 datasets and prior refuse-to-file letter for his "somewhat cautious" stance. For Sarepta Therapeutics (SRPT), Rama sees a net positive read-through from a favorable panel, on the potential for an accelerated path forward for golodirsen in Exon 53 DMD. Further, a negative panel is likely to be viewed as Translarna-specific, playing out as a net neutral for Sarepta, the analyst tells investors in a research note. He does not see "major fundamental downside risk" for Sarepta shares going into PTC's panel. Rama keeps a Neutral rating on PTC and Overweight rating on Sarepta.
09/27/17
LEER
09/27/17
NO CHANGE
LEER
Outperform
Sarepta doesn't see read through from PTC AdComm, says Leerink
After hosting Sarepta (SRPT) executives, Leerink analyst Joseph Schwartz noted management stated they do not anticipate any read through to Sarepta's exon skipping drugs from the advisory committee meeting to discuss PTC Therapeutics' (PTCT) ataluren as the therapies have different mechanisms and address different disease states. Additionally, the company said Exondys 51's U.S. launch has exceeded expectations, sales outside the U.S. are expected to be slower than U.S. sales, that they see a potential FDA filing for golodirsen in Q1 of 2018 and that they will update guidance in 2018. Schwartz keeps an Outperform rating on Sarepta shares.

TODAY'S FREE FLY STORIES

SVU

Supervalu

$18.90

0.085 (0.45%)

14:40
10/17/17
10/17
14:40
10/17/17
14:40
Options
Short-term call buying in SuperValu as shares slip into earnings »

Short-term call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

HES

Hess Corp.

$45.67

-0.37 (-0.80%)

14:30
10/17/17
10/17
14:30
10/17/17
14:30
Options
Hefty spread in Hess as a bullish position is adjusted »

Hefty spread in Hess as a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

DAL

Delta Air Lines

$52.91

-0.71 (-1.32%)

, MSG

Madison Square Garden

$215.84

-1.91 (-0.88%)

14:27
10/17/17
10/17
14:27
10/17/17
14:27
Hot Stocks
Delta expands MSG, MSG Networks partnership »

Delta (DAL) has renewed…

DAL

Delta Air Lines

$52.91

-0.71 (-1.32%)

MSG

Madison Square Garden

$215.84

-1.91 (-0.88%)

MSGN

MSG Networks

$21.03

0.275 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

MOH

Molina Healthcare

$61.64

1.78 (2.97%)

, UNH

UnitedHealth

$205.36

12.16 (6.29%)

14:27
10/17/17
10/17
14:27
10/17/17
14:27
Periodicals
Senator says bipartisan deal reached to stabilize ObamaCare, The Hill reports »

Republican Senator Lamar…

MOH

Molina Healthcare

$61.64

1.78 (2.97%)

UNH

UnitedHealth

$205.36

12.16 (6.29%)

CNC

Centene

$93.61

2.6901 (2.96%)

WCG

WellCare

$173.81

5.89 (3.51%)

CI

Cigna

$188.26

3.27 (1.77%)

ANTM

Anthem

$189.00

5.24 (2.85%)

HNT

Health Net

HUM

Humana

$241.96

4.785 (2.02%)

AET

Aetna

$155.62

4.18 (2.76%)

THC

Tenet

$13.31

0.4 (3.10%)

UHS

Universal Health

$108.19

2.59 (2.45%)

LPNT

LifePoint

$55.80

0.8 (1.45%)

HCA

HCA Healthcare

$77.14

1.95 (2.59%)

CYH

Community Health

$6.13

0.23 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

14:25
10/17/17
10/17
14:25
10/17/17
14:25
General news
Fed discount rate meeting minutes: 11 of 12 Banks voted for an unchanged »

Fed discount rate meeting…

ORI

Old Republic

$19.53

-0.24 (-1.21%)

14:21
10/17/17
10/17
14:21
10/17/17
14:21
Hot Stocks
Breaking Hot Stocks news story on Old Republic »

Old Republic trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTN

Vail Resorts

$218.22

1.7975 (0.83%)

14:20
10/17/17
10/17
14:20
10/17/17
14:20
Options
Call buyers in Vail Resorts as shares see strength »

Call buyers in Vail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

SVU

Supervalu

$18.77

-0.04 (-0.21%)

14:18
10/17/17
10/17
14:18
10/17/17
14:18
Technical Analysis
Technical Earnings Preview: Supervalu at multi-year lows ahead of results »

The stock has been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

$NSD

NASDAQ Market Internals

14:17
10/17/17
10/17
14:17
10/17/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$39.76

0.09 (0.23%)

, NVDA

Nvidia

$197.93

3.34 (1.72%)

14:16
10/17/17
10/17
14:16
10/17/17
14:16
Periodicals
Intel unveils new family of chips to take on Nvidia in AI, The Verge says »

Intel (INTC) has unveiled…

INTC

Intel

$39.76

0.09 (0.23%)

NVDA

Nvidia

$197.93

3.34 (1.72%)

SFTBF

SoftBank

$89.80

0.9 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 30

    Oct

  • 01

    Nov

$NYE

NYSE Market Internals

14:16
10/17/17
10/17
14:16
10/17/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORI

Old Republic

$19.53

-0.245 (-1.24%)

14:11
10/17/17
10/17
14:11
10/17/17
14:11
Hot Stocks
Old Republic says Q3 to include operating charges of $150M »

Old Republic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVI

Navient

$11.73

0.11 (0.95%)

14:10
10/17/17
10/17
14:10
10/17/17
14:10
Options
Call buyers in Navient ahead of earnings »

Call buyers in Navient…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

UNP

Union Pacific

$110.09

-2 (-1.78%)

14:08
10/17/17
10/17
14:08
10/17/17
14:08
Periodicals
Breaking Periodicals news story on Union Pacific »

Union Pacific initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

PACW

PacWest Bancorp

$48.09

0.13 (0.27%)

14:05
10/17/17
10/17
14:05
10/17/17
14:05
Downgrade
PacWest Bancorp rating change  »

PacWest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 09

    Nov

  • 13

    Nov

  • 14

    Nov

MOH

Molina Healthcare

$60.74

0.88 (1.47%)

, UNH

UnitedHealth

$204.93

11.73 (6.07%)

14:01
10/17/17
10/17
14:01
10/17/17
14:01
Periodicals
Senator Alexander says deal reached to shore up ACA markets, Bloomberg says »

Bloomberg cites Senator…

MOH

Molina Healthcare

$60.74

0.88 (1.47%)

UNH

UnitedHealth

$204.93

11.73 (6.07%)

CNC

Centene

$92.84

1.92 (2.11%)

WCG

WellCare

$172.72

4.8 (2.86%)

CI

Cigna

$187.49

2.5 (1.35%)

ANTM

Anthem

$187.60

3.8392 (2.09%)

HNT

Health Net

HUM

Humana

$241.08

3.905 (1.65%)

AET

Aetna

$155.17

3.7303 (2.46%)

HCA

HCA Healthcare

$75.63

0.44 (0.59%)

CYH

Community Health

$5.97

0.065 (1.10%)

THC

Tenet

$12.79

-0.12 (-0.93%)

UHS

Universal Health

$106.78

1.18 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

ORI

Old Republic

$19.54

-0.23 (-1.16%)

14:01
10/17/17
10/17
14:01
10/17/17
14:01
Hot Stocks
Breaking Hot Stocks news story on Old Republic »

Old Republic trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$128.76

1.035 (0.81%)

14:00
10/17/17
10/17
14:00
10/17/17
14:00
Hot Stocks
Deere wins trademark lawsuit against FIMCO »

U.S. District Court in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

XLF

Financial Select Sector

$26.13

-0.17 (-0.65%)

14:00
10/17/17
10/17
14:00
10/17/17
14:00
Options
Whale of a trade in SPDR Financial ETF expresses a defensive view »

Whale of a trade in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

13:47
10/17/17
10/17
13:47
10/17/17
13:47
Periodicals
Amazon inks deals with apartment landlords for lockers, WSJ reports »

Amazon.com has signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

WMT

Wal-Mart

$85.81

0.065 (0.08%)

13:41
10/17/17
10/17
13:41
10/17/17
13:41
Periodicals
Wal-Mart's Lore: Company plans to acquire more startups, TechCrunch reports »

Wal-Mart eCommerce CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

FB

Facebook

$174.52

0.78 (0.45%)

13:41
10/17/17
10/17
13:41
10/17/17
13:41
Hot Stocks
Facebook's Regina Dugan says to leave company early next year »

Regina Dugan, the head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 01

    Nov

EEM

MSCI Emerging Markets Index

$46.43

-0.2011 (-0.43%)

13:40
10/17/17
10/17
13:40
10/17/17
13:40
Options
Defensive option play in iShares Emerging Markets ETF »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUM

Humana

$240.82

3.65 (1.54%)

13:32
10/17/17
10/17
13:32
10/17/17
13:32
Hot Stocks
Humana expands Medicare Advantage offerings in New Hampshire »

Humana has expanded the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ABT

Abbott

$54.95

0.315 (0.58%)

, USB

U.S. Bancorp

$53.89

-0.37 (-0.68%)

13:30
10/17/17
10/17
13:30
10/17/17
13:30
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ABT

Abbott

$54.95

0.315 (0.58%)

USB

U.S. Bancorp

$53.89

-0.37 (-0.68%)

SVU

Supervalu

$18.71

-0.1 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 17

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.